- Home
- VRCA vs MDAI Comparison
VRCA vs MDAI Comparison
Compare VRCA & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- MDAI
- Stock Information
- Founded
- VRCA 2013
- MDAI 2013
- Country
- VRCA United States
- MDAI United States
- Employees
- VRCA N/A
- MDAI N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- VRCA Health Care
- MDAI Health Care
- Exchange
- VRCA Nasdaq
- MDAI Nasdaq
- Market Cap
- VRCA 43.0M
- MDAI 34.8M
- IPO Year
- VRCA 2018
- MDAI N/A
- Fundamental
- Price
- VRCA $0.54
- MDAI $1.62
- Analyst Decision
- VRCA Hold
- MDAI Strong Buy
- Analyst Count
- VRCA 5
- MDAI 2
- Target Price
- VRCA $6.00
- MDAI $4.75
- AVG Volume (30 Days)
- VRCA 263.8K
- MDAI 271.9K
- Earning Date
- VRCA 05-13-2025
- MDAI 05-13-2025
- Dividend Yield
- VRCA N/A
- MDAI N/A
- EPS Growth
- VRCA N/A
- MDAI N/A
- EPS
- VRCA N/A
- MDAI N/A
- Revenue
- VRCA $7,179,000.00
- MDAI $29,962,000.00
- Revenue This Year
- VRCA $127.85
- MDAI N/A
- Revenue Next Year
- VRCA $105.09
- MDAI $86.26
- P/E Ratio
- VRCA N/A
- MDAI N/A
- Revenue Growth
- VRCA N/A
- MDAI 55.21
- 52 Week Low
- VRCA $0.38
- MDAI $0.82
- 52 Week High
- VRCA $9.36
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- VRCA 43.40
- MDAI 66.58
- Support Level
- VRCA $0.49
- MDAI $1.57
- Resistance Level
- VRCA $0.73
- MDAI $1.73
- Average True Range (ATR)
- VRCA 0.07
- MDAI 0.09
- MACD
- VRCA -0.01
- MDAI 0.04
- Stochastic Oscillator
- VRCA 10.77
- MDAI 82.61
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.